WCN26-6057 LUBIPROSTONE IN CHRONIC KIDNEY DISEASE: INSIGHTS FROM A PHASE 2 RANDOMIZED CONTROLLED TRIAL

Read full text Summarise with VIRAT
Authors: Shun Watanabe, Masaaki Nakayama, Takashi Yokoo, Satoru Sanada, Yoshifumi Ubara, Atsushi Komatsuda, Katsuhiko Asanuma, Yusuke Suzuki, Tsuneo Konta, Junichiro James Kazama, Kensei Taguchi, Kei Fukami
+3 more Takafumi Toyohara, Tetsuhiro Tanaka, Takaaki Abe
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Chronic kidney disease (CKD) progression is a major global health burden, and novel therapeutic strategies are urgently needed. Constipation is associated with accelerated CKD progression, yet the renoprotective mechanisms of laxatives remain poorly defined. We conducted a clinical trial in patients with CKD to evaluate the effects of lubiprostone, a chloride-channel activator, on renal function and to investigate underlying mechanisms, with a particular focus on interactions between the gut microbiome and host pathways.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Gastrointestinal motility and disorders Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104362–104362
Publication date
25 March 2026
Language
EN